Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-02545920 for Sub-optimally Controlled Schizophrenia
NCT01939548Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Oct 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mardepodect in schizophrenia, sponsored by Pfizer. Started Oct 2013; status: terminated.
02
Drugs
mardepodect
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01939548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01939548.